Acute Coronary Syndrome - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Coronary Syndrome - Pipeline Review, H2 2016, provides an overview of the Acute Coronary Syndrome (Cardiovascular) pipeline landscape.

Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Coronary Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome.

Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Coronary Syndrome (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Coronary Syndrome (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Coronary Syndrome (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Coronary Syndrome (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Acute Coronary Syndrome Overview 8
Therapeutics Development 9
Pipeline Products for Acute Coronary Syndrome - Overview 9
Acute Coronary Syndrome - Therapeutics under Development by Companies 10
Acute Coronary Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Acute Coronary Syndrome - Products under Development by Companies 14
Acute Coronary Syndrome - Companies Involved in Therapeutics Development 15
advanceCor GmbH 15
Arena Pharmaceuticals, Inc. 16
Ascendia Pharmaceuticals LLC 17
Athera Biotechnologies AB 18
Bayer AG 19
Cardiome Pharma Corp. 20
Cerenis Therapeutics Holding SA 21
CSL Limited 22
Esperion Therapeutics, Inc. 23
HitGen LTD 24
Japan Tobacco Inc. 25
Lee's Pharmaceutical Holdings Limited 26
LipimetiX Development Inc 27
MedImmune LLC 28
Pfizer Inc. 29
The Medicines Company 30
Verseon Corporation 31
Acute Coronary Syndrome - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
4-WF - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
AEM-28 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AEM-2802 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Biologics for Acute Coronary Syndrome - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CER-001 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
clopidogrel bisulphate - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
COR-2 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CSL-112 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
dalcetrapib - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MDCO-216 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
MEDI-6012 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PC-mAb - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
PF-06282999 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
PMC-6 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
PR-15 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
rivaroxaban - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
temanogrel hydrochloride - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
tirofiban hydrochloride - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
ZK-001 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Acute Coronary Syndrome - Dormant Projects 90
Acute Coronary Syndrome - Discontinued Products 92
Acute Coronary Syndrome - Product Development Milestones 94
Featured News & Press Releases 94
Sep 01, 2016: FDA Approves New AGGRASTAT Product Format 94
Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule 94
Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial 95
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics 96
Jul 07, 2016: Medicure Receives Response Letter from FDA on AGGRASTAT sNDA for New Indication 97
May 11, 2016: Medicure Files Application for New AGGRASTAT Product Format 98
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial 98
Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 99
Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy 101
Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015 103
Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients 103
Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides 104
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery 105
May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 106

Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 108
Disclaimer 109

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2016 15
Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 16
Acute Coronary Syndrome - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016 17
Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2016 18
Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2016 19
Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H2 2016 20
Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H2 2016 21
Acute Coronary Syndrome - Pipeline by CSL Limited, H2 2016 22
Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2016 23
Acute Coronary Syndrome - Pipeline by HitGen LTD, H2 2016 24
Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H2 2016 25
Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 26
Acute Coronary Syndrome - Pipeline by LipimetiX Development Inc, H2 2016 27
Acute Coronary Syndrome - Pipeline by MedImmune LLC, H2 2016 28
Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2016 29
Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2016 30
Acute Coronary Syndrome - Pipeline by Verseon Corporation, H2 2016 31
Assessment by Monotherapy Products, H2 2016 32
Number of Products by Stage and Target, H2 2016 34
Number of Products by Stage and Mechanism of Action, H2 2016 36
Number of Products by Stage and Route of Administration, H2 2016 38
Number of Products by Stage and Molecule Type, H2 2016 40
Acute Coronary Syndrome - Dormant Projects, H2 2016 90
Acute Coronary Syndrome - Dormant Projects (Contd..1), H2 2016 91
Acute Coronary Syndrome - Discontinued Products, H2 2016 92
Acute Coronary Syndrome - Discontinued Products (Contd..1), H2 2016 93